| dc.creator | Cussa, Jorgelina | |
| dc.creator | Juárez, Juliana M. | |
| dc.creator | Gómez Costa, Marcos B. | |
| dc.creator | Anunziata, Oscar A. | |
| dc.date | 2022-06-02T19:47:00Z | |
| dc.date | 2022-06-02T19:47:00Z | |
| dc.date | 2021 | |
| dc.date.accessioned | 2023-08-31T14:36:16Z | |
| dc.date.available | 2023-08-31T14:36:16Z | |
| dc.identifier | http://hdl.handle.net/20.500.12272/6602 | |
| dc.identifier | - | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/8548296 | |
| dc.description | Drug-controlled release systems can keep the level of drugs in precise doses in the body above the
optimal level and with low toxicity. We propose the LP-SBA-15 nanomaterial as a promising new
host for drug delivery systems because of its high biocompatibility, in vivo biodegradability, and low
toxicity. Ketorolac-LP-SBA-15 was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and
texture analysis, determining the adsorption capacity and its release, achieving the required
therapeutic efficacy. The host shows ordered mesoporous nanochannels with a diameter of 11-12
nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release the
LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental
data, being the Ritger-Peppas model followed by the Weibull model the best ones. In this work,
we show a promising drug storage material for effective encapsulation and controlled release of
KETO, achieving the required therapeutic efficacy. Studies indicate that KETO was adsorbed on the
channel surface of LP-SBA-15 without affecting the structure or chemical composition of KETO.
Controlled drug delivery systems can achieve precise delivery at the time and place of destination,
keeping the concentration of the drug at points in the body within the optimal range and below
the toxicity threshold. The study also demonstrates the storage capacity and release properties of LPSBA-
15 containing KETO. The release of KETO contained in LP-SBA-15 can offer a significant
improvement in the controlled release of the drug and the analgesic and anti-inflammatory effects,
positively influenced, by the links formed between the host and drug molecules and by diffusion
through the host porosity. The promising results we obtained for the release of the drug thoroughly
using the new material, reaching a rapid initial release rate, and maintaining a constant rate
afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range,
applying it largely to the treatment of diseases that require a rapid response. | |
| dc.description | Fil: Juárez, Juliana M.. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina. | |
| dc.description | Fil: Anunziata, Oscar A.. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina. | |
| dc.description | Fil: Gómez Costa, Marcos B.. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina. | |
| dc.description | Fil: Cussa, Jorgelina. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina. | |
| dc.format | pdf | |
| dc.language | eng | |
| dc.rights | openAccess | |
| dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | |
| dc.rights | Oscar A. Anunziata | |
| dc.rights | _X_Atribución (Attribution): En cualquier explotación de la obra autorizada por la licencia será necesario reconocer la autoría (obligatoria en todos los casos).
_X_No comercial (Non Commercial): La explotación de la obra queda limitada a usos no comerciales.
_X_Sin obras derivadas (No Derivate Works): La autorización para explotar la obra no incluye la posibilidad de crear una obra derivada (traducciones, adaptaciones, etc.).
_X_Compartir igual (Share Alike): La explotación autorizada incluye la creación de obras derivadas siempre que se mantenga la misma licencia al ser divulgadas. | |
| dc.subject | ketorolac | |
| dc.subject | LP-SBA-15 | |
| dc.subject | nanostructured host | |
| dc.subject | drug-delivering device | |
| dc.title | Preparation, characterization and mathematical modeling of keterolac release conteined in lpsba-15 host | |
| dc.type | info:eu-repo/semantics/conferenceObject | |
| dc.type | publisherVersion | |
